Abstracts tagged "quality of life"

Abstract Number: 0749 • ACR Convergence 2021
Association Between Clinically Meaningful Back Pain Improvement and Patient-reported Outcomes and Disease Activity in Patients with Ankylosing Spondylitis: Results from a Phase 2/3 Trial
Xenofon Baraliakos¹, Louis Bessette², Carlo Salvarani³, Naijun Chen⁴, Ralph Lippe⁵, Jayeshkumar Patel⁴, In-Ho Song⁴, Patrick Zueger⁶ and Philippe Goupille⁷, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Laval University, Québec City, QC, Canada, ³Rheumatology Unit, Azienda USL-IRCCS di Reggio Emilia and Universita di Moderna e Reggio Emilia, Reggio Emilia, Italy, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁶AbbVie Inc., Mettawa, IL, ⁷University hospital of Tours, Rheumatology department, Tours, France
Background/Purpose: Back pain is the hallmark disease feature for patients (pts) with AS. However, the relationship between back pain and other patient-centric outcomes and disease…
Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Shannon Grabich¹, Eilleen Farrelly², Robert Ortmann³, Michael Pollack⁴ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…
Abstract Number: 1779 • ACR Convergence 2021
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Nancy Shadick¹, Kumiko Schnock², Vivi Feather², Jing Cui³, Gabriela Maica², Alexa Marshall², Wynona Francis², Muibat Yussuff², Lourdes Maria Perez Chada², Michael E. Weinblatt² and Joseph Merola⁴, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
Abstract Number: 0754 • ACR Convergence 2021
Bridging the Gap Between Patient-Reported Outcomes and Disease-Related Outcomes in Lupus – a Feasibility Study
Shivani Garg¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with SLE have significantly worse health-related quality of life (QOL) at an earlier age compared to patients with other chronic diseases. This highlights…
Abstract Number: 1274 • ACR Convergence 2021
Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Manuel Ugarte-Gil¹, Rocio Gamboa-Cardenas², Cristina Reategui-Sokolova³, Victor Pimentel-Quiroz¹, Mariela Medina⁴, Claudia Elera-Fitzcarrald², Francisco Zevallos⁴, Cesar Pastor-Asurza⁵, Federico Zazzetti⁶, Chetan Karyekar⁷, Risto Perich-Campos⁵ and Graciela Alarcn⁸, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁷Janssen R&D, Spring House, PA, ⁸University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flares in SLE patients, regardless of their severity, have been associated with damage accrual. However, their impact on HRQoL has not been fully evaluated.…
Abstract Number: 1786 • ACR Convergence 2021
Association of the Improvement of Synovitis and Enthesitis with Quality of Life/Patient Reported Outcomes in Patients with PsA Treated with Ixekizumab
Lars Erik Kristensen¹, Dennis McGonagle², Martin Rudwaleit³, Hideto Kameda⁴, Thorsten Holzkaemper⁵, Celine El Baou⁶ and Josef Smolen⁷, ¹Bispebjerg-Frederiksberg Hospital, Copenhagen,, Denmark, ²University of Leeds, Leeds, United Kingdom, ³Bielefeld University, Rheumatology, Klinikum Bielefeld, Berlin, Germany, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵Eli Lilly and Company, Bad Homburg, Germany, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Medical University of Vienna, Vienna, Austria
Background/Purpose: PsA is an inflammatory rheumatic disease with manifestations including synovitis and enthesitis. During extensive study programs, IXE has shown a treatment effect across domains…
Abstract Number: 0151 • ACR Convergence 2020
More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois³, Diane Tin⁴, Carol Hitchon⁵, Louis Bessette⁶, Carter Thorne⁴, Janet Pope⁷, Gilles Boire⁸, Edward Keystone⁹, Vivian Bykerk¹⁰, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹McGill University, Montreal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Laval University, Quebec, Canada, ⁷Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁸Universite de Sherbrooke, Sherbrooke, Canada, ⁹The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Although DMARDs are essential for early aggressive control of RA to reduce symptoms and disability, medication adherence is variable. Beliefs about the necessity of…
Abstract Number: 0725 • ACR Convergence 2020
A Data Science Evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) Questionnaire for Improving Management of JIA Patients
Humbert Quesada-Masachs¹, Michalis Faloutsos², Shomit Ghose³, Sara Marsal⁴, Consuelo Modesto⁴ and Estefania Quesada-Masachs⁵, ¹University of California Riverside, San Diego, ²University of California Riverside, Riverside, ³University of California Berkeley, San Francisco, ⁴Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁵Hospital Universitari Vall d'Hebron, San Diego
Background/Purpose: The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a questionnaire developed to comprehensively assess Juvenile Idiopathic Arthritis (JIA) patients. Despite being translated into 54…
Abstract Number: 1273 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on the Fibromyalgia Symptoms of SLE Patients
Rebecca Sadun¹, Jennifer Rogers², Kai Sun¹, Karissa Grier¹, Lisa Criscione-Schreiber³, Mithu Maheswaranathan¹, Jayanth Doss¹ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Many patients with SLE experience symptoms of chronic pain and fatigue, often meeting criteria for fibromyalgia (FM). In this study, we sought to examine…
Abstract Number: 0156 • ACR Convergence 2020
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
Wojciech Tański¹, Mariusz Chabowski², Natalia Świątoniowska-Lonc³ and Beata Jankowska-Polańska³, ¹4th Military Teaching Hospital, Wrocław, Poland, ²4th Military Teaching Hospital, Wroclaw Medical University, Wrocław, Poland, ³Wroclaw Medical University, Wrocław, Poland
Background/Purpose: Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease involving the axial skeleton, entheses and peripheral joints, and may occur together with extra-articular manifestations, such…
Abstract Number: 0877 • ACR Convergence 2020
Improvements in Global Functioning and Health-related Quality of Life and Their Association with Disease Activity and Functional Improvement in Patients with Active Ankylosing Spondylitis Treated with Upadacitinib
Uta Kiltz¹, Joachim Sieper², Atul Deodhar³, Patrick Zueger⁴, In-Ho Song⁴, Naijun Chen⁴ and Désirée van der Heijde⁵, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Herne, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴AbbVie Inc., North Chicago, IL, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Upadacitinib (UPA) has been shown to be effective and well tolerated in patients with active ankylosing spondylitis (AS) [1]. However, improvements in global functioning…
Abstract Number: 1284 • ACR Convergence 2020
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
Sarah Lieber¹, Patricia Katz², Joshua Baker³, Deanna Jannat-Khah⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²University of California, San Francisco, Novato, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital for Special Surgery, New York City, NY
Background/Purpose: Patients with SLE are at risk for both skeletal muscle loss and increased adiposity, which may predispose to worse health-related quality of life. Decreased…
Abstract Number: 0166 • ACR Convergence 2020
Prevalence and Impact of Unacceptable Symptom State Among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation’s 2019 Annual Survey
Alexis Ogdie¹, George Gondo², Joseph Merola³, Stacie Bell⁴ and Alice Gottlieb⁵, ¹University of Pennsylvania, Philadelphia, PA, ²National Psoriasis Foundation, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ⁴National Psoriasis Foundation, Portland, ⁵Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Despite many efficacious therapies for PsA, many patients do not achieve remission. Ongoing disease activity leads to many downstream effects including diminished functional ability,…
Abstract Number: 0900 • ACR Convergence 2020
Achievement of Low Disease Activity According to BASDAI with Ixekizumab in Patients with Axial Spondyloarthritis: 16-Week Results from the COAST Trials
Denis Poddubnyy¹, Xavier Juanola², Clément Prati³, Hagen Russ⁴, Yves Schymura⁴, Soyi Liu-Leage⁵, Mani Haschemi Nassab⁴ and Jean Dudler⁶, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain, ³Service de Rhumatologie, Hôpital Jean-Minjoz , Besançon, France, Besançon, France, ⁴Eli Lilly and Company, Indianapolis, Indiana, USA, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Rheumatology, HFR Fribourg - Hospital Cantonal, Fribourg, Switzerland, Fribourg, Switzerland
Background/Purpose: The efficacy of ixekizumab (IXE), a selective interleukin-17A antagonist, was assessed in patients (pts) with axial SpA (axSpA) in three Phase 3, randomized, double-blind,…
Abstract Number: 1285 • ACR Convergence 2020
Association of Frailty with Disability Is Not Attenuated by Lean Body Mass in Women with SLE
Sarah Lieber¹, Patricia Katz², Joshua Baker³, Deanna Jannat-Khah⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²University of California, San Francisco, Novato, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital for Special Surgery, New York City, NY
Background/Purpose: Frailty has been associated with disability and mortality in SLE. Whether this association is confounded by sarcopenia, a degenerative loss of muscle mass and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].